Cargando…
The Novel Small-molecule Annexin-A1 Mimetic, Compound 17b, Elicits Vasoprotective Actions in Streptozotocin-induced Diabetic Mice
The formyl peptide receptor (FPR) family are a group of G-protein coupled receptors that play an important role in the regulation of inflammatory processes. It is well-established that activation of FPRs can have cardioprotective properties. Recently, more stable small-molecule FPR1/2 agonists have...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073122/ https://www.ncbi.nlm.nih.gov/pubmed/32085666 http://dx.doi.org/10.3390/ijms21041384 |
_version_ | 1783506565112791040 |
---|---|
author | Marshall, Sarah A Qin, Cheng Xue Jelinic, Maria O’Sullivan, Kelly Deo, Minh Walsh, Jesse Li, Mandy Parry, Laura J Ritchie, Rebecca H. Leo, Chen Huei |
author_facet | Marshall, Sarah A Qin, Cheng Xue Jelinic, Maria O’Sullivan, Kelly Deo, Minh Walsh, Jesse Li, Mandy Parry, Laura J Ritchie, Rebecca H. Leo, Chen Huei |
author_sort | Marshall, Sarah A |
collection | PubMed |
description | The formyl peptide receptor (FPR) family are a group of G-protein coupled receptors that play an important role in the regulation of inflammatory processes. It is well-established that activation of FPRs can have cardioprotective properties. Recently, more stable small-molecule FPR1/2 agonists have been described, including both Compound 17b (Cmpd17b) and Compound 43 (Cmpd43). Both agonists activate a range of signals downstream of FPR1/2 activation in human-engineered FPR-expressing cells, including ERK1/2 and Akt. Importantly, Cmpd17b (but not Cmpd43) favours bias away from intracellular Ca(2+) mobilisation in this context, which has been associated with greater cardioprotection in response to Cmpd17b over Cmpd43. However, it is unknown whether these FPR agonists impact vascular physiology and/or elicit vasoprotective effects in the context of diabetes. First, we localized FPR1 and FPR2 receptors predominantly in vascular smooth muscle cells in the aortae of male C57BL/6 mice. We then analysed the vascular effects of Cmpd17b and Cmpd43 on the aorta using wire-myography. Cmpd17b but not Cmpd43 evoked a concentration-dependent relaxation of the mouse aorta. Removal of the endothelium or blockade of endothelium-derived relaxing factors using pharmacological inhibitors had no effect on Cmpd17b-evoked relaxation, demonstrating that its direct vasodilator actions were endothelium-independent. In aortae primed with elevated K(+) concentration, increasing concentrations of CaCl(2) evoked concentration-dependent contraction that is abolished by Cmpd17b, suggesting the involvement of the inhibition of Ca(2+) mobilisation via voltage-gated calcium channels. Treatment with Cmpd17b for eight weeks reversed endothelial dysfunction in STZ-induced diabetic aorta through the upregulation of vasodilator prostanoids. Our data indicate that Cmpd17b is a direct endothelium-independent vasodilator, and a vasoprotective molecule in the context of diabetes. |
format | Online Article Text |
id | pubmed-7073122 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70731222020-03-19 The Novel Small-molecule Annexin-A1 Mimetic, Compound 17b, Elicits Vasoprotective Actions in Streptozotocin-induced Diabetic Mice Marshall, Sarah A Qin, Cheng Xue Jelinic, Maria O’Sullivan, Kelly Deo, Minh Walsh, Jesse Li, Mandy Parry, Laura J Ritchie, Rebecca H. Leo, Chen Huei Int J Mol Sci Article The formyl peptide receptor (FPR) family are a group of G-protein coupled receptors that play an important role in the regulation of inflammatory processes. It is well-established that activation of FPRs can have cardioprotective properties. Recently, more stable small-molecule FPR1/2 agonists have been described, including both Compound 17b (Cmpd17b) and Compound 43 (Cmpd43). Both agonists activate a range of signals downstream of FPR1/2 activation in human-engineered FPR-expressing cells, including ERK1/2 and Akt. Importantly, Cmpd17b (but not Cmpd43) favours bias away from intracellular Ca(2+) mobilisation in this context, which has been associated with greater cardioprotection in response to Cmpd17b over Cmpd43. However, it is unknown whether these FPR agonists impact vascular physiology and/or elicit vasoprotective effects in the context of diabetes. First, we localized FPR1 and FPR2 receptors predominantly in vascular smooth muscle cells in the aortae of male C57BL/6 mice. We then analysed the vascular effects of Cmpd17b and Cmpd43 on the aorta using wire-myography. Cmpd17b but not Cmpd43 evoked a concentration-dependent relaxation of the mouse aorta. Removal of the endothelium or blockade of endothelium-derived relaxing factors using pharmacological inhibitors had no effect on Cmpd17b-evoked relaxation, demonstrating that its direct vasodilator actions were endothelium-independent. In aortae primed with elevated K(+) concentration, increasing concentrations of CaCl(2) evoked concentration-dependent contraction that is abolished by Cmpd17b, suggesting the involvement of the inhibition of Ca(2+) mobilisation via voltage-gated calcium channels. Treatment with Cmpd17b for eight weeks reversed endothelial dysfunction in STZ-induced diabetic aorta through the upregulation of vasodilator prostanoids. Our data indicate that Cmpd17b is a direct endothelium-independent vasodilator, and a vasoprotective molecule in the context of diabetes. MDPI 2020-02-18 /pmc/articles/PMC7073122/ /pubmed/32085666 http://dx.doi.org/10.3390/ijms21041384 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Marshall, Sarah A Qin, Cheng Xue Jelinic, Maria O’Sullivan, Kelly Deo, Minh Walsh, Jesse Li, Mandy Parry, Laura J Ritchie, Rebecca H. Leo, Chen Huei The Novel Small-molecule Annexin-A1 Mimetic, Compound 17b, Elicits Vasoprotective Actions in Streptozotocin-induced Diabetic Mice |
title | The Novel Small-molecule Annexin-A1 Mimetic, Compound 17b, Elicits Vasoprotective Actions in Streptozotocin-induced Diabetic Mice |
title_full | The Novel Small-molecule Annexin-A1 Mimetic, Compound 17b, Elicits Vasoprotective Actions in Streptozotocin-induced Diabetic Mice |
title_fullStr | The Novel Small-molecule Annexin-A1 Mimetic, Compound 17b, Elicits Vasoprotective Actions in Streptozotocin-induced Diabetic Mice |
title_full_unstemmed | The Novel Small-molecule Annexin-A1 Mimetic, Compound 17b, Elicits Vasoprotective Actions in Streptozotocin-induced Diabetic Mice |
title_short | The Novel Small-molecule Annexin-A1 Mimetic, Compound 17b, Elicits Vasoprotective Actions in Streptozotocin-induced Diabetic Mice |
title_sort | novel small-molecule annexin-a1 mimetic, compound 17b, elicits vasoprotective actions in streptozotocin-induced diabetic mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073122/ https://www.ncbi.nlm.nih.gov/pubmed/32085666 http://dx.doi.org/10.3390/ijms21041384 |
work_keys_str_mv | AT marshallsaraha thenovelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice AT qinchengxue thenovelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice AT jelinicmaria thenovelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice AT osullivankelly thenovelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice AT deominh thenovelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice AT walshjesse thenovelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice AT limandy thenovelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice AT parrylauraj thenovelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice AT ritchierebeccah thenovelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice AT leochenhuei thenovelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice AT marshallsaraha novelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice AT qinchengxue novelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice AT jelinicmaria novelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice AT osullivankelly novelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice AT deominh novelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice AT walshjesse novelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice AT limandy novelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice AT parrylauraj novelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice AT ritchierebeccah novelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice AT leochenhuei novelsmallmoleculeannexina1mimeticcompound17belicitsvasoprotectiveactionsinstreptozotocininduceddiabeticmice |